The clinical efficacy of anti-CD38 monoclonal antibodies, such as daratumumab and isatuximab, has been demonstrated in various phases of multiple myeloma treatment, including newly diagnosed, relapsed, and refractory settings (47–53). Here, CD38 is linked to plasma cell myeloma.